Back to search

Peptide record

TPDB07425

Antibacterial Antifungal Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07425
Antibacterial Antifungal Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept ToxinPred 3.0
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Antifungal, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
Sequence
INLKAIAALAKKLF
Physicochemical Analysis
C73H128N18O16
RDCEQGHMPSTWYV
A
1513.93
10.84
3
0
10
+3
-0.72
1.086
167.86
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
0
0.00
1
Residue Composition
number
4
A
0
R
1
N
0
D
0
C
0
E
0
Q
0
G
0
H
2
I
3
L
3
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 4 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 3 K: 3 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
14
C73H128N18O16
1513.93
10.84
+3
-0.72
1.086
Evidence Records 32 records
Evidence 1 Activity

Activity

MIC
Antibacterial
16-32 µg/mL

Target

Staphylococcus aureus CCRC12652 or CCRC15211

Source & Reference

NA

Other

Active against Gram+ S. aureus CCRC12652 or CCRC15211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml
Evidence 2 Activity

Activity

MIC
Antibacterial
1.5 µg/mL

Target

S. xylosus

Source & Reference

NA

Other

Active against Gram+ S. aureus CCRC12652 or CCRC15211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp
Evidence 3 Activity

Activity

MIC
Antibacterial
8 µg/mL

Target

S. alactolyticus

Source & Reference

NA

Other

nst Gram+ S. aureus CCRC12652 or CCRC15211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae
Evidence 4 Activity

Activity

MIC
Antibacterial
4 µg/mL

Target

C. koseri

Source & Reference

NA

Other

5211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Ch
Evidence 5 Activity

Activity

MIC
Antibacterial
4-8 µg/mL

Target

Escherichia coli BL21 or JM109 Amp

Source & Reference

NA

Other

. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium C
Evidence 6 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

Klebsiella pneumoniae CCRC10694

Source & Reference

NA

Other

(MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelyti
Evidence 7 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

S. Choleraesuis

Source & Reference

NA

Other

g/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and
Evidence 8 Activity

Activity

MIC
Antibacterial
32 µg/mL

Target

S. typhimurium CCRC12947

Source & Reference

NA

Other

(MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including
Evidence 9 Activity

Activity

MIC
Antibacterial
16 µg/mL

Target

V. parahamelytics CCRC10806

Source & Reference

NA

Other

(MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including A. baumannii and its clinical strains (MIC 2
Evidence 10 Activity

Activity

MIC
Antibacterial
96 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

NA

Other

S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including A. baumannii and its clinical strains (MIC 2-16 ug/ml).
Evidence 11 Activity

Activity

MIC
Antibacterial
2-16 µg/mL

Target

A. baumannii and its clinical strains

Source & Reference

NA

Other

, V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including A. baumannii and its clinical strains (MIC 2-16 ug/ml).
Evidence 12 Activity

Activity

MIC
Antifungal
16-32 µg/mL

Target

Staphylococcus aureus CCRC12652 or CCRC15211

Source & Reference

Antifungipept

Other

Active against Gram+ S. aureus CCRC12652 or CCRC15211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml
Evidence 13 Activity

Activity

MIC
Antifungal
1.5 µg/mL

Target

S. xylosus

Source & Reference

Antifungipept

Other

Active against Gram+ S. aureus CCRC12652 or CCRC15211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp
Evidence 14 Activity

Activity

MIC
Antifungal
8 µg/mL

Target

S. alactolyticus

Source & Reference

Antifungipept

Other

nst Gram+ S. aureus CCRC12652 or CCRC15211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae
Evidence 15 Activity

Activity

MIC
Antifungal
4 µg/mL

Target

C. koseri

Source & Reference

Antifungipept

Other

5211 (MIC 16-32 ug/ml), S. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Ch
Evidence 16 Activity

Activity

MIC
Antifungal
4-8 µg/mL

Target

Escherichia coli BL21 or JM109 Amp

Source & Reference

Antifungipept

Other

. xylosus (MIC 1.5 ug/ml), S. alactolyticus (MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium C
Evidence 17 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

Klebsiella pneumoniae CCRC10694

Source & Reference

Antifungipept

Other

(MIC 8 ug/ml), Gram- C. koseri (MIC 4 ug/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelyti
Evidence 18 Activity

Activity

MIC
Antifungal
16 µg/mL

Target

S. Choleraesuis

Source & Reference

Antifungipept

Other

g/ml), E. coli BL21 or JM109 Amp (MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and
Evidence 19 Activity

Activity

MIC
Antifungal
32 µg/mL

Target

S. typhimurium CCRC12947

Source & Reference

Antifungipept

Other

(MIC 4-8 ug/ml), K. pneumoniae CCRC10694 (MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including
Evidence 20 Activity

Activity

MIC
Antifungal
16 µg/mL

Target

V. parahamelytics CCRC10806

Source & Reference

Antifungipept

Other

(MIC 32 ug/ml), S. Choleraesuis (MIC 16 ug/ml), S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including A. baumannii and its clinical strains (MIC 2
Evidence 21 Activity

Activity

MIC
Antifungal
96 µg/mL

Target

Pseudomonas aeruginosa

Source & Reference

Antifungipept

Other

S. typhimurium CCRC12947 (MIC 32 ug/ml), V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including A. baumannii and its clinical strains (MIC 2-16 ug/ml).
Evidence 22 Activity

Activity

MIC
Antifungal
2-16 µg/mL

Target

A. baumannii and its clinical strains

Source & Reference

Antifungipept

Other

, V. parahamelytics CCRC10806 (MIC 16 ug/ml), and P. aeruginosa (MIC 96 ug/ml), including A. baumannii and its clinical strains (MIC 2-16 ug/ml).
Evidence 23 Activity

Activity

2% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
2% Hemolysis | 32 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 24 Activity

Activity

7% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
7% Hemolysis | 64 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 25 Activity

Activity

15% Hemolysis
Toxicity
128 µg/mL
Hemolytic Cytotoxic
15% Hemolysis | 128 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 26 Activity

Activity

35% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
35% Hemolysis | 256 | µg/mL | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 27 Activity

Activity

0% Hemolysis
Toxicity
32 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 32 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 28 Activity

Activity

3% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
3% Hemolysis | 64 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 29 Activity

Activity

13% Hemolysis
Toxicity
128 µg/mL
Hemolytic Cytotoxic
13% Hemolysis | 128 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 30 Activity

Activity

37% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
37% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structural and biological characterization of mastoparans in the venom of Vespa species in Taiwan. | Peptides | 2011
Evidence 31 Activity

Activity

<5% Hemolysis
Toxicity
8 µM
Hemolytic Cytotoxic
<5% Hemolysis | 8 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influence of hydrophobicity on the antimicrobial activity of helical antimicrobial peptides: a study focusing on three mastoparans. | Mol Divers | 2024
Evidence 32 Activity

Activity

48% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
48% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influence of hydrophobicity on the antimicrobial activity of helical antimicrobial peptides: a study focusing on three mastoparans. | Mol Divers | 2024